journal
MENU ▼
Read by QxMD icon Read
search

Immunotherapy

journal
https://www.readbyqxmd.com/read/30511887/%C3%AE-pd-l1-mab-enhances-the-abscopal-effect-of-hypo-fractionated-radiation-by-attenuating-pd-l1-expression-and-inducing-cd8-t-cell-infiltration
#1
Hui Wang, Xiangjie Lin, Yuan Luo, Shaoxing Sun, Xiaoli Tian, Yingming Sun, Shimin Zhang, Jing Chen, Junhong Zhang, Xuefeng Liu, Huan Liu, Yan Gong, Conghua Xie
AIM: We investigated a promising cooperative combination of radiotherapy (RT) and programmed death ligand 1 (PD-L1) monoclonal antibodies (mAb) in both local and abscopal tumors. MATERIALS & METHODS: C57BL/6 mice were randomly grouped and received RT, α-PD-L1 mAb or combination therapy 13 days after implantation of Lewis lung carcinoma cells. Flow cytometry and immunohistochemistry analyses demonstrated CD8+ T-cell infiltration and PD-L1 expression in tumor issue...
December 4, 2018: Immunotherapy
https://www.readbyqxmd.com/read/30511592/a-study-of-the-clinical-characteristics-and-prognosis-of-advanced-mucosal-and-cutaneous-melanoma-in-a-chinese-population
#2
Yong Zhang, Xiaomin Fu, Yalong Qi, Quanli Gao
AIM: To investigate the characteristics and prognosis of melanoma in a Chinese population. MATERIALS & METHODS:  Total of 162 advanced melanoma patients were analyzed retrospectively. Kaplan-Meier method and Log rank test were used for survival analysis. RESULTS: The median progression-free survival of mucosal and cutaneous melanoma patients was 13 versus 8 months (p = 0.005), 14 versus 10 months in immunotherapy group (p = 0.022), 6 versus 4 months in chemotherapy group (p = 0...
December 4, 2018: Immunotherapy
https://www.readbyqxmd.com/read/30499734/safety-and-efficacy-of-intravenous-immunoglobulin-flebogamma-%C3%A2-10-dif-in-patients-with-immune-thrombocytopenic-purpura
#3
Shashikant Apte, Jordi Navarro-Puerto, Sharat Damodar, Vijay Ramanan, Joseph John, Giraldo Kato, Cecil Ross, Chirag Shah, Marcela Torres, Chieh-Lin 'Kathy' Fu, Karen Rucker, Paul Pinciaro, Gladis Barrera, Maria Esperança Aragonés, Jaume Ayguasanosa
AIM: To evaluate the safety and efficacy of 10% intravenous immunoglobulin (IVIG; Flebogamma®  10% DIF) in individuals with chronic immune thrombocytopenic purpura (ITP). PATIENTS & METHODS: Patients aged 3-70 years, diagnosed with chronic ITP, received 1 g/kg IVIG over two consecutive days. RESULTS:  64 evaluable patients (51 adults, 13 children) with chronic ITP received IVIG. The primary efficacy end point (increased platelet counts from ≤20 × 109 /l to ≥50 × 109 /l by day 8) was achieved by 81...
November 30, 2018: Immunotherapy
https://www.readbyqxmd.com/read/30407098/factors-associated-with-immunotherapy-selection-in-patients-with-advanced-melanoma
#4
Richard W Joseph, Alicia C Shillington, Cynthia Macahilig, Scott J Diede, Vaidehi Dave, Qing Harshaw, Frank Xiaoqing Liu
AIM: To explore factors associated with pembrolizumab (PEMBRO) versus ipilimumab + nivolumab (IPI+NIVO) selection in advanced melanoma. MATERIALS & METHODS:  Total of 12 academic and satellite clinics contributed to this study. Descriptive and logistic regression analyses were conducted to explore associations between clinical characteristics and treatment choice. RESULTS:  Total of 400 patients were included: 200 PEMBRO and 200 IPI+NIVO...
November 8, 2018: Immunotherapy
https://www.readbyqxmd.com/read/30381988/intracellular-activation-of-complement-c3-in-paneth-cells-improves-repair-of-intestinal-epithelia-during-acute-injury
#5
Jian Zhang, Jinning Ye, Yufeng Ren, Jidong Zuo, Weigang Dai, Yulong He, Min Tan, Wu Song, Yujie Yuan
AIM: To explore whether Paneth cells (PCs) and complement system collaborate in the repair of enteric epithelia during acute gastrointestinal injury (AGI). METHODS: Wild-type C57BL/6 mice were employed to induce AGI by performing colon ascendens stent surgery, with sham-operated as control. Exogenous C3 treatment was applied at 6-h postsurgery. After 48 h, overall survival, intestinal damage severity, and C3 intracellular activation were assessed in both epithelial cells and PCs...
November 1, 2018: Immunotherapy
https://www.readbyqxmd.com/read/30350739/combination-of-pd-1-blockade-and-retronectin-activated-cytokine-induced-killer-in-preheavily-treated-non-small-cell-lung-cancer-a-retrospective-study
#6
Lingdi Zhao, Lu Han, Yong Zhang, Tiepeng Li, Yonghao Yang, Wei Li, Yiman Shang, Hongwei Lin, Quanli Gao
AIM: To analyze the efficacy of PD-1 blockade combined with RetroNectin-activated cytokine-induced killer (R-CIK) cells in preheavily treated advanced non-small-cell lung cancer (NSCLC). METHODS: We retrospectively analyzed patients with advanced NSCLC who received PD-1 blockade combined with R-CIK cells whose treatments failed at least two regimens. RESULTS: The median number of previous treatment regimens was three (range: 2-7). Partial remission was achieved in two patients, stable disease in four patients and one patient experienced progressive disease...
October 23, 2018: Immunotherapy
https://www.readbyqxmd.com/read/30474483/immunotherapy-foreword-2018
#7
Mike Gregg
To all of our readers, the Future Medicine editorial office would like to thank you for your continued readership over 2018 and I hope you have a fantastic Christmas and New Year. I would also like to thank our esteemed editorial board, peer reviewers and contributing authors for their continued support. We very much look forward to working with you all in 2019 and seeing the journal continue to progress. In this foreword, we will present some highlights from the last 12 months in addition to looking forward to the year ahead...
November 2018: Immunotherapy
https://www.readbyqxmd.com/read/30474482/the-behavior-of-italian-allergists-in-prescribing-allergen-immunotherapy-for-house-dust-mites-allergy
#8
Giorgio Ciprandi, Cristoforo Incorvaia, Maria Angela Tosca
The meeting 'Clinical Evidence, Extracts Quality and Biotechnology Innovation in Allergen Immunotherapy' held in Trieste (Italy) on 1 October 2017 concerned the outcomes of a real-world survey conducted on a group of Italian allergists about allergen immunotherapy (AIT) for house dust mites allergy. It pointed out: allergist's confidence that AIT should be prescribed continuously; tablets seem to be well accepted by patients and effective in most subjects with a fast onset of action (3-6 months); combined score for symptom severity and medication use is universally assessed; there is disagreement about the diagnosis of house dust mites allergy, the quote of AIT prescription, the choice for AIT route of administration, assessment of serum IgE and perception of patient's adherence...
November 2018: Immunotherapy
https://www.readbyqxmd.com/read/30474481/non-small-cell-lung-cancer-homing-peptide-labeled-dendrimers-selectively-transfect-lung-cancer-cells
#9
Gregory E Holt, Pirouz Daftarian
AIM: Lung cancer gene therapies require reagents to selectively transfect lung tumors after systemic administration. MATERIALS & METHODS: We created a reagent called NSCLC-NP by attaching a peptide with binding affinity for lung cancer to polyamidoamine dendrimers. The positively charged dendrimers electrostatically bind negatively charged nucleic acids, inhibit endogenous nucleases and transfect cells targeted by the attached peptide. RESULTS: In vitro, NSCLC-NP complexed to DNA plasmids bound and transfected three human lung cancer cell lines producing protein expression of the plasmid's gene...
November 2018: Immunotherapy
https://www.readbyqxmd.com/read/30474477/the-forgotten-role-of-adjuvant-immune-checkpoint-inhibitors-in-preventing-melanoma-brain-metastasis
#10
Elie El Rassy, Fadi Farhat, Joseph Kattan
No abstract text is available yet for this article.
November 2018: Immunotherapy
https://www.readbyqxmd.com/read/30474476/efficacy-and-safety-of-pd-1-inhibitors-for-treating-advanced-melanoma-a-systematic-review-and-meta-analysis
#11
Jing Li, Jian Gu
AIM: We conducted a meta-analysis to systematically review the efficacy and safety of programmed cell death 1 (PD-1) inhibitors for advanced melanoma. STUDY DESIGN: The relevant studies of the randomized controlled trials in melanoma patients treated with PD-1 inhibitors were retrieved and the systematic evaluation was conducted. Databases were searched till June 2018. RESULTS: PD-1 inhibitors significantly improved the progression-free survival, overall survival and overall response rate in patients with advanced melanoma...
November 2018: Immunotherapy
https://www.readbyqxmd.com/read/30474475/risk-of-fatigue-in-cancer-patients-treated-with-anti-programmed-cell-death-1-anti-programmed-cell-death-ligand-1-agents-a-systematic-review-and-meta-analysis
#12
Matteo Santoni, Alessandro Conti, Sebastiano Buti, Melissa Bersanelli, Laura Foghini, Francesco Piva, Matteo Giulietti, Lukas Lusuardi, Nicola Battelli
AIM: We aimed to assess the incidence and relative risk (RR) of fatigue in cancer patients treated with anti programmed cell death-1 (PD-1) and anti programmed cell death ligand-1 (PD-L1) agents. PATIENTS & METHODS: Eligible studies were selected according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Incidence, RR and 95% CIs were calculated using random or fixed-effects models. RESULTS: Thirty-eight studies were included in this analysis, with a total of 11,719 patients...
November 2018: Immunotherapy
https://www.readbyqxmd.com/read/30326788/tolerability-and-positive-efficacy-results-after-subcutaneous-immunotherapy-with-parietaria-judaica-depot-extract
#13
Ernesto Enrique, Dolores Hernández-Fernandez de Rojas, Pilar Alba, Isabel Flores, Noelia Colomer, Carmen Andreu, María Cruz Gómez-Fernández, Araitz Landeta, Juan Antonio Asturias, Alberto Martínez, Begoña Madariaga-Goirigolzarri
AIM: To evaluate tolerability and efficacy of Parietaria judaica subcutaneous immunotherapy on patients with allergic rhinoconjunctivitis. PATIENTS & METHODS: 51 patients were assigned to build-up scheme (six increasing doses) of P. judaica depot native extract, plus three maintenance monthly administrations. RESULTS: Out of 470 administered doses, only 3.8% elicited systemic reactions (1.5% nonspecific and 2.3% grade I). Concerning the exploratory efficacy parameters: cutaneous reactivity at the final visit versus baseline was significantly decreased; specific titers of IgG and IgG4 increased significantly and patients showed a significant decrease in the rhinitis symptoms score...
October 2018: Immunotherapy
https://www.readbyqxmd.com/read/30326787/influenza-vaccine-indication-during-therapy-with-immune-checkpoint-inhibitors-a-transversal-challenge-the-invidia-study
#14
Melissa Bersanelli, Diana Giannarelli, Paola Castrignanò, Giuseppe Fornarini, Stefano Panni, Francesca Mazzoni, Marcello Tiseo, Sabrina Rossetti, Elisabetta Gambale, Ernesto Rossi, Anselmo Papa, Alessio Cortellini, Cristian Lolli, Raffaele Ratta, Maria Michiara, Michele Milella, Emmanuele De Luca, Mariella Sorarù, Claudia Mucciarini, Francesco Atzori, Giuseppe L Banna, Leonardo La Torre, Maria G Vitale, Francesco Massari, Sara E Rebuzzi, Gaetano Facchini, Giovanni Schinzari, Silverio Tomao, Simona Bui, Vanja Vaccaro, Giuseppe Procopio, Ugo De Giorgi, Matteo Santoni, Corrado Ficorella, Roberto Sabbatini, Antonio Maestri, Clara Natoli, Michele De Tursi, Massimo Di Maio, Elena Rapacchi, Annagrazia Pireddu, Teodoro Sava, Helga Lipari, Francesca Comito, Elena Verzoni, Francesco Leonardi, Sebastiano Buti
AIM: Considering the unmet need for the counseling of cancer patients treated with immune checkpoint inhibitors (CKI) about influenza vaccination, an explorative study was planned to assess flu vaccine efficacy in this population. METHODS: INVIDIa was a retrospective, multicenter study, enrolling consecutive advanced cancer outpatients receiving CKI during the influenza season 2016-2017. RESULTS: Of 300 patients, 79 received flu vaccine. The incidence of influenza syndrome was 24...
October 2018: Immunotherapy
https://www.readbyqxmd.com/read/30326786/harnessing-immune-checkpoints-for-cancer-therapy
#15
Dass S Vinay, Byoung S Kwon
Immunomodulatory antibodies that directly trigger and reawaken suppressed T-cell effector function are termed 'checkpoint inhibitors'. CTLA-4 and PD-1/PD-L1 molecules are the most studied inhibitory immune check points against cancer and because of this therapeutic property have entered the clinic for treating a variety of tumor types. The results so far demonstrate a positive impact on cancer remission. Preclinical studies have demonstrated that targeting a number of other T-cell surface molecules including both positive and negative immune regulators, also possesses strong antitumor activity...
October 2018: Immunotherapy
https://www.readbyqxmd.com/read/30326785/atezolizumab-induced-sarcoid-like-granulomatous-reaction-in-a-patient-with-urothelial-cell-carcinoma
#16
Michael A Mitchell, Kevin Hogan, Kayvan Amjadi
A 61-year-old woman with locally advanced, high-grade urothelial cell carcinoma was treated with the anti-programmed death-ligand 1 antibody atezolizumab. She initially received neoadjuvant chemotherapy and surgery that led to clinical and radiographic remission at the time of atezolizumab initiation. Within 3 months she developed new mediastinal and hilar lymphadenopathy as well as pulmonary nodules in a pattern characteristic of pulmonary sarcoidosis. Mediastinal lymph node biopsy by endobronchial ultrasound demonstrated noncaseating granulomas without evidence of malignancy or infection...
October 2018: Immunotherapy
https://www.readbyqxmd.com/read/30296868/mesenchymal-stromal-cells-in-the-treatment-of-perianal-fistulas-in-crohn-s-disease
#17
Jesús Castro-Poceiro, Agnès Fernández-Clotet, Julián Panés
Significant unmet needs remain in patients with Crohn's disease and perianal fistulas. Mesenchymal stromal cells have potent immunomodulatory actions. The Phase II studies reported efficacy of local injection of mesenchymal stromal cells to achieve closure of fistulas. A Phase III trial demonstrated that in patients with Crohn's disease and refractory complex perianal fistulas, a single injection of 120 × 106 cells was superior to local injection of placebo associated with the same surgical procedure, in obtaining closure of the fistula tracts together with absence of abscesses >2 cm, 24 weeks after the injection, a stringent combined primary end point...
October 2018: Immunotherapy
https://www.readbyqxmd.com/read/30244623/comparative-study-of-adjuvants-for-allergen-specific-immunotherapy-in-a-murine-model
#18
María Vázquez de la Torre, Maria Luisa Baeza, Laura Nájera, José Manuel Zubeldia
AIM: To compare the immunological and clinical changes induced by allergen-specific immunotherapy (AIT) using different adjuvants. MATERIALS & METHODS: Olea europaea pollen-sensitized mice were treated with olea plus aluminum hydroxide, calcium phosphate, monophosphoryl lipid A (MPL) or immunostimulatory sequences (ISS). RESULTS: Aluminum hydroxide seems to drive initially to a Th2-type response. Bacteria-derived adjuvants (MPL and ISS) skew the immune response toward Th1 and Treg pathways...
October 2018: Immunotherapy
https://www.readbyqxmd.com/read/30175642/sequential-treatment-approaches-in-the-management-of-braf-wild-type-advanced-melanoma-a-cost-effectiveness-analysis
#19
Ahmad Tarhini, Agnes Benedict, David McDermott, Sumati Rao, Apoorva Ambavane, Komal Gupte-Singh, Javier Sabater, Corey Ritchings, Valerie Aponte-Ribero, Meredith M Regan, Michael Atkins
AIM: To evaluate the cost-effectiveness of treatment sequences with checkpoint inhibitors in patients with BRAF wild-type melanoma. MATERIALS & METHODS: Using a discrete event simulation model, cost and health outcomes were estimated. Pooled data from CheckMate 067/069 trials were used to calculate survival outcomes including treatment-free interval extrapolated over a patient's lifetime. Costs accounted for treatment, administration, toxicity, and disease management...
October 2018: Immunotherapy
https://www.readbyqxmd.com/read/30236027/immunotherapy-beyond-progression-in-advanced-renal-cell-carcinoma-a-case-report-and-review-of-the-literature
#20
Sara Elena Rebuzzi, Giacomo Bregni, Massimiliano Grassi, Azzurra Damiani, Michele Buscaglia, Sebastiano Buti, Giuseppe Fornarini
Immunotherapy is associated with different response patterns compared with chemotherapy and targeted therapy, including delayed response and stabilization after progression (pseudoprogression). According to new immuno-based response criteria, immunotherapy can be continued after radiological progression when a clinical benefit is observed. We report a case of an advanced renal cell carcinoma patient treated with nivolumab, who developed clinical benefit and delayed radiological response after initial progression...
September 2018: Immunotherapy
journal
journal
42164
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"